These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 21131038)
21. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL; Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620 [TBL] [Abstract][Full Text] [Related]
22. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Kimby E; Nygren P; Glimelius B; Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935 [TBL] [Abstract][Full Text] [Related]
23. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A; Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876 [TBL] [Abstract][Full Text] [Related]
24. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study. Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291 [TBL] [Abstract][Full Text] [Related]
25. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Biondi A; Schrappe M; De Lorenzo P; Castor A; Lucchini G; Gandemer V; Pieters R; Stary J; Escherich G; Campbell M; Li CK; Vora A; Aricò M; Röttgers S; Saha V; Valsecchi MG Lancet Oncol; 2012 Sep; 13(9):936-45. PubMed ID: 22898679 [TBL] [Abstract][Full Text] [Related]
26. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699 [TBL] [Abstract][Full Text] [Related]
27. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Lawson SE; Harrison G; Richards S; Oakhill A; Stevens R; Eden OB; Darbyshire PJ Br J Haematol; 2000 Mar; 108(3):531-43. PubMed ID: 10759711 [TBL] [Abstract][Full Text] [Related]
28. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol. Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691 [TBL] [Abstract][Full Text] [Related]
29. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Jabbour E; Richard-Carpentier G; Sasaki Y; Konopleva M; Patel K; Roberts K; Gu Z; Wang F; Huang X; Sasaki K; Short NJ; Jain N; Ravandi F; Daver NG; Kadia TM; Alvarado Y; DiNardo CD; Issa GC; Pemmaraju N; Garcia-Manero G; Verstovsek S; Wang S; Khoury JD; Jorgensen J; Champlin R; Khouri I; Kebriaei P; Schroeder H; Khouri M; Mullighan CG; Takahashi K; O'Brien SM; Kantarjian H Lancet Haematol; 2020 Jul; 7(7):e523-e533. PubMed ID: 32589978 [TBL] [Abstract][Full Text] [Related]
30. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893 [TBL] [Abstract][Full Text] [Related]
31. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G; Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589 [TBL] [Abstract][Full Text] [Related]
32. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. Bassan R; Rohatiner AZ; Lerede T; Di Bona E; Rambaldi A; Pogliani E; Rossi G; Fabris P; Morandi S; Casula P; Carter M; Lambertenghi-Deliliers G; Lister TA; Barbui T Hematol J; 2000; 1(4):226-34. PubMed ID: 11920195 [TBL] [Abstract][Full Text] [Related]
33. Mitoxantrone in first-relapse paediatric ALL: the ALL R3 trial. Schrappe M Lancet; 2010 Dec; 376(9757):1968-70. PubMed ID: 21131040 [No Abstract] [Full Text] [Related]
34. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Eden OB; Lilleyman JS; Richards S; Shaw MP; Peto J Br J Haematol; 1991 Jun; 78(2):187-96. PubMed ID: 2064956 [TBL] [Abstract][Full Text] [Related]
35. A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group. Testi AM; Del Giudice I; Arcese W; Moleti ML; Giona F; Basso G; Biondi A; Conter V; Messina C; Rondelli R; Micozzi A; Micalizzi C; Barisone E; Locatelli F; Dini G; Aricò M; Casale F; Comis M; Ladogana S; Lippi A; Mura R; Pinta MF; Santoro N; Valsecchi MG; Masera G; Mandelli F; Br J Haematol; 2002 Sep; 118(3):741-7. PubMed ID: 12181040 [TBL] [Abstract][Full Text] [Related]
36. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409 [TBL] [Abstract][Full Text] [Related]
37. ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse. Giona F; Testi AM; Rondelli R; Amadori S; Arcese W; Meloni G; Moleti ML; Ceci A; Pillon M; Madon E; Comis M; Pession A; Mandelli F Br J Haematol; 1997 Dec; 99(3):671-7. PubMed ID: 9401083 [TBL] [Abstract][Full Text] [Related]
38. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996 [TBL] [Abstract][Full Text] [Related]
39. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. Marks DI; Kirkwood AA; Rowntree CJ; Aguiar M; Bailey KE; Beaton B; Cahalin P; Castleton AZ; Clifton-Hadley L; Copland M; Goldstone AH; Kelly R; Lawrie E; Lee S; McMillan AK; McMullin MF; Menne TF; Mitchell RJ; Moorman AV; Patel B; Patrick P; Smith P; Taussig D; Yallop D; Alapi KZ; Fielding AK Lancet Haematol; 2022 Apr; 9(4):e262-e275. PubMed ID: 35358441 [TBL] [Abstract][Full Text] [Related]